Circulating biomarkers that predict incident dementia

Alzheimer's Research and Therapy

Volumn 6, Issue 1, 2014, Pages

  Weinstein, Galit ^a,b   Seshadri, Sudha ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AMYLIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; BETA SECRETASE 1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CERAMIDE; CHOLESTEROL ESTER TRANSFER PROTEIN; CLUSTERIN; CYANOCOBALAMIN; FOLIC ACID; GLYCOSPHINGOLIPID; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; INTERLEUKIN 6; LEPTIN; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; OXYSTEROL; SPHINGOLIPID; SPHINGOMYELIN; THYROTROPIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ALZHEIMER DISEASE; BLOOD VESSEL INJURY; CHOLESTEROL BLOOD LEVEL; DEGENERATIVE DISEASE; DEMENTIA; DISEASE ASSOCIATION; DNA DAMAGE; GENETIC VARIABILITY; HUMAN; INFLAMMATION; METABOLOMICS; MILD COGNITIVE IMPAIRMENT; NERVE CELL DEGENERATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK;

EID: 84893035315     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt235     Document Type: Review

References (133)

1. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. S Seshadri, PA Wolf, Lancet Neurol 2007 6 1106 1114 10.1016/S1474-4422(07)70291-0 18031707 (Pubitemid 350123607)
2. Global prevalence of dementia: a Delphi consensus study. CP Ferri, M Prince, C Brayne, H Brodaty, L Fratiglioni, M Ganguli, K Hall, K Hasegawa, H Hendrie, Y Huang, A Jorm, C Mathers, PR Menezes, E Rimmer, M Scazufca, Lancet 2005 366 2112 2117 16360788 (Pubitemid 41797645)
3. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV Washington, DC: American Psychiatric Association 4 1994
4. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. GM McKhann, DS Knopman, H Chertkow, BT Hyman, CR Jack Jr, CH Kawas, WE Klunk, WJ Koroshetz, JJ Manly, R Mayeux, RC Mohs, JC Morris, MN Rossor, P Scheltens, MC Carrillo, B Thies, S Weintraub, CH Phelps, Alzheimers Dement 2011 7 263 269 10.1016/j.jalz.2011.03. 005 21514250
5. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. B Dubois, HH Feldman, C Jacova, ST Dekosky, P Barberger-Gateau, J Cummings, A Delacourte, D Galasko, S Gauthier, G Jicha, K Meguro, J O'Brien, F Pasquier, P Robert, M Rossor, S Salloway, Y Stern, PJ Visser, P Scheltens, Lancet Neurol 2007 6 734 746 10.1016/S1474-4422(07)70178-3 17616482 (Pubitemid 47058377)
6. Plasma biomarkers for Alzheimer's disease: much needed but tough to find. C Bazenet, S Lovestone, Biomark Med 2012 6 441 454 10.2217/bmm.12.48 22917146
7. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. F Song, A Poljak, GA Smythe, P Sachdev, Brain Res Rev 2009 61 69 80 10.1016/j.brainresrev.2009.05.003 19464319
8. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. LA Farrer, LA Cupples, JL Haines, B Hyman, WA Kukull, R Mayeux, RH Myers, MA Pericak-Vance, N Risch, CM van Duijn, JAMA 1997 278 1349 1356 10.1001/jama.1997.03550160069041 9343467 (Pubitemid 27449696)
9. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. C Patterson, JW Feightner, A Garcia, GY Hsiung, C MacKnight, AD Sadovnick, CMAJ 2008 178 548 556 10.1503/cmaj.070796 18299540 (Pubitemid 351413998)
10. Genome-wide analysis of genetic loci associated with Alzheimer disease. S Seshadri, AL Fitzpatrick, MA Ikram, AL DeStefano, V Gudnason, M Boada, JC Bis, AV Smith, MM Carassquillo, JC Lambert, D Harold, EM Schrijvers, R Ramirez-Lorca, S Debette, WT Longstreth Jr, AC Janssens, VS Pankratz, JF Dartigues, P Hollingworth, T Aspelund, I Hernandez, A Beiser, LH Kuller, PJ Koudstaal, DW Dickson, C Tzourio, R Abraham, C Antunez, Y Du, JI Rotter, et al. JAMA 2010 303 1832 1840 10.1001/jama.2010.574 20460622
11. Identifying earlier Alzheimer's disease: insights from the preclinical and prodromal phases. JL Molinuevo, R Sanchez-Valle, A Llado, J Fortea, D Bartres-Faz, L Rami, Neurodegener Dis 2012 10 158 160 10.1159/000332806 22156554
12. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. AM Fagan, RJ Perrin, Biomark Med 2012 6 455 476 10.2217/bmm.12.42 22917147
13. Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease. K Herholz, Biomark Med 2012 6 431 439 10.2217/bmm.12.51 22917145
14. Proteome-based plasma biomarkers for Alzheimer's disease. A Hye, S Lynham, M Thambisetty, M Causevic, J Campbell, HL Byers, C Hooper, F Rijsdijk, SJ Tabrizi, S Banner, CE Shaw, C Foy, M Poppe, N Archer, G Hamilton, J Powell, RG Brown, P Sham, M Ward, S Lovestone, Brain 2006 129 3042 3050 10.1093/brain/awl279 17071923 (Pubitemid 44684524)
15. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? T Wyss-Coray, Nat Med 2006 12 1005 1015 16960575 (Pubitemid 44353380)
16. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. E Rogaeva, Y Meng, JH Lee, Y Gu, T Kawarai, F Zou, T Katayama, CT Baldwin, R Cheng, H Hasegawa, F Chen, N Shibata, KL Lunetta, R Pardossi-Piquard, C Bohm, Y Wakutani, LA Cupples, KT Cuenco, RC Green, L Pinessi, I Rainero, S Sorbi, A Bruni, R Duara, RP Friedland, R Inzelberg, W Hampe, H Bujo, YQ Song, OM Andersen, et al. Nat Genet 2007 39 168 177 10.1038/ng1943 17220890 (Pubitemid 46184347)
17. Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. AE Sanders, C Wang, M Katz, CA Derby, N Barzilai, L Ozelius, RB Lipton, JAMA 2010 303 150 158 10.1001/jama.2009.1988 20068209
18. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. KJ Anstey, DM Lipnicki, LF Low, Am J Geriatr Psychiatry 2008 16 343 354 18448847
19. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. M Kivipelto, EL Helkala, MP Laakso, T Hanninen, M Hallikainen, K Alhainen, S Iivonen, A Mannermaa, J Tuomilehto, A Nissinen, H Soininen, Ann Intern Med 2002 137 149 155 10.7326/0003-4819-137-3-200208060- 00006 12160362 (Pubitemid 34827510)
20. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. IL Notkola, R Sulkava, J Pekkanen, T Erkinjuntti, C Ehnholm, P Kivinen, J Tuomilehto, A Nissinen, Neuroepidemiology 1998 17 14 20 10.1159/000026149 9549720 (Pubitemid 28153361)
21. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. A Solomon, M Kivipelto, B Wolozin, J Zhou, RA Whitmer, Dement Geriatr Cogn Disord 2009 28 75 80 10.1159/000231980 19648749
22. Midlife cardiovascular risk factors and risk of dementia in late life. RA Whitmer, S Sidney, J Selby, SC Johnston, K Yaffe, Neurology 2005 64 277 281 10.1212/01.WNL.0000149519.47454.F2 15668425
23. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. S Kalmijn, D Foley, L White, CM Burchfiel, JD Curb, H Petrovitch, GW Ross, RJ Havlik, LJ Launer, Arterioscler Thromb Vasc Biol 2000 20 2255 2260 10.1161/01.ATV.20.10. 2255 11031212
24. The 32-year relationship between cholesterol and dementia from midlife to late life. MM Mielke, PP Zandi, H Shao, M Waern, S Ostling, X Guo, C Bjorkelund, L Lissner, I Skoog, DR Gustafson, Neurology 2010 75 1888 1895 10.1212/WNL.0b013e3181feb2bf 21068429
25. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. R Stewart, LR White, QL Xue, LJ Launer, Arch Neurol 2007 64 103 107 10.1001/archneur.64.1.103 17210816 (Pubitemid 46072431)
26. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. ZS Tan, S Seshadri, A Beiser, PW Wilson, DP Kiel, M Tocco, RB D'Agostino, PA Wolf, Arch Intern Med 2003 163 1053 1057 10.1001/archinte. 163.9.1053 12742802 (Pubitemid 36548931)
27. High total cholesterol levels in late life associated with a reduced risk of dementia. MM Mielke, PP Zandi, M Sjogren, D Gustafson, S Ostling, B Steen, I Skoog, Neurology 2005 64 1689 1695 10.1212/01.WNL.0000161870.78572.A5 15911792 (Pubitemid 40695799)
28. Relation of plasma lipids to Alzheimer disease and vascular dementia. C Reitz, MX Tang, J Luchsinger, R Mayeux, Arch Neurol 2004 61 705 714 10.1001/archneur.61.5.705 15148148 (Pubitemid 38637688)
29. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. G Li, JB Shofer, WA Kukull, ER Peskind, DW Tsuang, JC Breitner, W McCormick, JD Bowen, L Teri, GD Schellenberg, EB Larson, Neurology 2005 65 1045 1050 10.1212/01.wnl.0000178989.87072.11 16217057 (Pubitemid 41429629)
30. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. T Yoshitake, Y Kiyohara, I Kato, T Ohmura, H Iwamoto, K Nakayama, S Ohmori, K Nomiyama, H Kawano, K Ueda, K Sueishi, M Tsuneyoshi, M Fujishima, Neurology 1995 45 1161 1168 10.1212/WNL.45.6.1161 7783883
31. Cholesterol homeostasis and function in neurons of the central nervous system. FW Pfrieger, Cell Mol Life Sci 2003 60 1158 1171 12861382 (Pubitemid 36791918)
32. Linking lipids to Alzheimer's disease: cholesterol and beyond. G Di Paolo, TW Kim, Nat Rev Neurosci 2011 12 284 296 10.1038/nrn3012 21448224
33. Role of cholesterol in APP metabolism and its significance in Alzheimer's disease pathogenesis. M Maulik, D Westaway, JH Jhamandas, S Kar, Mol Neurobiol 2013 47 37 63 10.1007/s12035-012-8337-y 22983915
34. Oxysterols and neurodegenerative diseases. I Bjorkhem, A Cedazo-Minguez, V Leoni, S Meaney, Mol Aspects Med 2009 30 171 179 10.1016/j.mam.2009.02.001 19248803
35. The link between altered cholesterol metabolism and Alzheimer's disease. P Gamba, G Testa, B Sottero, S Gargiulo, G Poli, G Leonarduzzi, Ann N Y Acad Sci 2012 1259 54 64 10.1111/j.1749-6632.2012.06513.x 22758637
36. Markers of cholesterol metabolism in the brain show stronger associations with cerebrovascular disease than Alzheimer's disease. TM Hughes, LH Kuller, OL Lopez, JT Becker, RW Evans, K Sutton-Tyrrell, C Rosano, J Alzheimers Dis 2012 30 53 61 22377780
37. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. C Reitz, MX Tang, N Schupf, JJ Manly, R Mayeux, JA Luchsinger, Arch Neurol 2010 67 1491 1497 10.1001/archneurol.2010.297 21149810
38. Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. MM Mielke, VV Bandaru, NJ Haughey, J Xia, LP Fried, S Yasar, M Albert, V Varma, G Harris, EB Schneider, PV Rabins, K Bandeen-Roche, CG Lyketsos, MC Carlson, Neurology 2012 79 633 641 10.1212/WNL.0b013e318264e380 22815558
39. Cobalamin deficiency and neuropsychiatric disorders. V Herbert, N Engl J Med 1988 319 1733 1735 3205271 (Pubitemid 19019585)
40. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. J Lindenbaum, EB Healton, DG Savage, JC Brust, TJ Garrett, ER Podell, PD Marcell, SP Stabler, RH Allen, N Engl J Med 1988 318 1720 1728 10.1056/NEJM198806303182604 3374544
41. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. B Hooshmand, A Solomon, I Kareholt, J Leiviska, M Rusanen, S Ahtiluoto, B Winblad, T Laatikainen, H Soininen, M Kivipelto, Neurology 2010 75 1408 1414 10.1212/WNL.0b013e3181f88162 20956786
42. Vitamin B§ssub§12§esub§ status, cognitive decline and dementia: a systematic review of prospective cohort studies. F O'Leary, M Allman-Farinelli, S Samman, Br J Nutr 2012 108 1948 1961 10.1017/ S0007114512004175 23084026
43. Genetic, dietary, and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and women in Singapore. SM Saw, JM Yuan, CN Ong, K Arakawa, HP Lee, GA Coetzee, MC Yu, Am J Clin Nutr 2001 73 232 239 11157318 (Pubitemid 32111746)
44. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. M Arnadottir, B Hultberg, P Nilsson-Ehle, H Thysell, Scand J Clin Lab Invest 1996 56 41 46 10.3109/00365519609088586 8850171 (Pubitemid 26064671)
45. Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. MN Haan, JW Miller, AE Aiello, RA Whitmer, WJ Jagust, DM Mungas, LH Allen, R Green, Am J Clin Nutr 2007 85 511 517 17284751 (Pubitemid 46220956)
46. Changes in folate, vitamin B12 and homocysteine associated with incident dementia. JM Kim, R Stewart, SW Kim, IS Shin, SJ Yang, HY Shin, JS Yoon, J Neurol Neurosurg Psychiatry 2008 79 864 868 10.1136/jnnp.2007.131482 18252751
47. Homocysteine and folate as risk factors for dementia and Alzheimer disease. G Ravaglia, P Forti, F Maioli, M Martelli, L Servadei, N Brunetti, E Porcellini, F Licastro, Am J Clin Nutr 2005 82 636 643 16155278
48. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. S Seshadri, A Beiser, J Selhub, PF Jacques, IH Rosenberg, RB D'Agostino, PW Wilson, PA Wolf, N Engl J Med 2002 346 476 483 10.1056/NEJMoa011613 11844848 (Pubitemid 34441738)
49. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. S Kalmijn, LJ Launer, J Lindemans, ML Bots, A Hofman, MM Breteler, Am J Epidemiol 1999 150 283 289 10.1093/oxfordjournals.aje.a010000 10430233 (Pubitemid 29344955)
50. Plasma homocysteine levels and risk of Alzheimer disease. JA Luchsinger, MX Tang, S Shea, J Miller, R Green, R Mayeux, Neurology 2004 62 1972 1976 10.1212/01.WNL.0000129504.60409.88 15184599 (Pubitemid 38738206)
51. Plasma homocysteine and risk of mild cognitive impairment. C Reitz, MX Tang, J Miller, R Green, JA Luchsinger, Dement Geriatr Cogn Disord 2009 27 11 17 10.1159/000182421 19088473
52. Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer's disease? S Seshadri, J Alzheimers Dis 2006 9 393 398 16917147 (Pubitemid 44253353)
53. Homocysteine accelerates endothelial cell senescence. D Xu, R Neville, T Finkel, FEBS Lett 2000 470 20 24 10.1016/S0014-5793(00)01278-3 10722838 (Pubitemid 30155616)
54. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. II Kruman, TS Kumaravel, A Lohani, WA Pedersen, RG Cutler, Y Kruman, N Haughey, J Lee, M Evans, MP Mattson, J Neurosci 2002 22 1752 1762 11880504 (Pubitemid 35386293)
55. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. PI Ho, D Ortiz, E Rogers, TB Shea, J Neurosci Res 2002 70 694 702 10.1002/jnr.10416 12424737 (Pubitemid 35397143)
56. Homocysteic acid as a putative excitatory amino acid neurotransmitter: I. Postsynaptic characteristics at N-methyl-D-aspartate-type receptors on striatal cholinergic interneurons. J Lehmann, C Tsai, PL Wood, J Neurochem 1988 51 1765 1770 10.1111/j.1471-4159.1988.tb01157.x 2846784 (Pubitemid 19010963)
57. Glutamate-induced homocysteic acid release from astrocytes: possible implication in glia-neuron signaling. B Benz, G Grima, KQ Do, Neuroscience 2004 124 377 386 10.1016/j.neuroscience.2003.08.067 14980387 (Pubitemid 38229657)
58. Roles of homocysteine in cell metabolism: old and new functions. M Medina, JL Urdiales, MI Amores-Sanchez, Eur J Biochem 2001 268 3871 3882 10.1046/j.1432-1327.2001.02278.x 11453979 (Pubitemid 32878521)
59. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. H Jakubowski, Faseb J 1999 13 2277 2283 10593875
60. Inhibition of Na+, K + -ATPase activity by the metabolites accumulating in homocystinuria. EL Streck, AI Zugno, B Tagliari, C Wannmacher, M Wajner, AT Wyse, Metab Brain Dis 2002 17 83 91 10.1023/A:1015594111778 12083340 (Pubitemid 34655047)
61. Endoplasmic reticulum stress-inducible protein, Herp, enhances presenilin-mediated generation of amyloid beta-protein. X Sai, Y Kawamura, K Kokame, H Yamaguchi, H Shiraishi, R Suzuki, T Suzuki, M Kawaichi, T Miyata, T Kitamura, B De Strooper, K Yanagisawa, H Komano, J Biol Chem 2002 277 12915 12920 10.1074/jbc.M112372200 11799129 (Pubitemid 34952658)
62. Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. AR White, X Huang, MF Jobling, CJ Barrow, K Beyreuther, CL Masters, AI Bush, R Cappai, J Neurochem 2001 76 1509 1520 10.1046/j.1471-4159.2001.00178.x 11238735 (Pubitemid 32198255)
63. Protein phosphatase 2A methylation: a link between elevated plasma homocysteine and Alzheimer's disease. SB Vafai, JB Stock, FEBS Lett 2002 518 1 4 10.1016/S0014-5793(02)02702-3 11997007 (Pubitemid 34454953)
64. Homocysteine and atherothrombosis. GN Welch, J Loscalzo, N Engl J Med 1998 338 1042 1050 10.1056/NEJM199804093381507 9535670 (Pubitemid 28180407)
65. Hyperhomocysteinemia due to short-term folate deprivation is related to electron microscopic changes in the rat brain. JM Kim, H Lee, N Chang, J Nutr 2002 132 3418 3421 12421861 (Pubitemid 35304254)
66. Risk of dementia in diabetes mellitus: a systematic review. GJ Biessels, S Staekenborg, E Brunner, C Brayne, P Scheltens, Lancet Neurol 2006 5 64 74 10.1016/S1474-4422(05)70284-2 16361024 (Pubitemid 41790697)
67. Systemic and brain metabolic dysfunction as a new paradigm for approaching Alzheimer's dementia. V Giordano, G Peluso, M Iannuccelli, P Benatti, R Nicolai, M Calvani, Neurochem Res 2007 32 555 567 10.1007/s11064-006-9125-8 16915364 (Pubitemid 46481288)
68. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. S Craft, Arch Neurol 2009 66 300 305 10.1001/archneurol.2009.27 19273747
69. Hyperinsulinemia and risk of Alzheimer disease. JA Luchsinger, MX Tang, S Shea, R Mayeux, Neurology 2004 63 1187 1192 10.1212/01.WNL.0000140292.04932.87 15477536 (Pubitemid 39350015)
70. Impaired insulin secretion increases the risk of Alzheimer disease. E Ronnemaa, B Zethelius, J Sundelof, J Sundstrom, M Degerman-Gunnarsson, C Berne, L Lannfelt, L Kilander, Neurology 2008 71 1065 1071 10.1212/01.wnl.0000310646. 32212.3a 18401020
71. Fasting insulin and incident dementia in an elderly population of Japanese-American men. R Peila, BL Rodriguez, LR White, LJ Launer, Neurology 2004 63 228 233 10.1212/01.WNL.0000129989.28404.9B 15277613 (Pubitemid 38971119)
72. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. EM Schrijvers, JC Witteman, EJ Sijbrands, A Hofman, PJ Koudstaal, MM Breteler, Neurology 2010 75 1982 1987 10.1212/WNL.0b013e3181ffe4f6 21115952
73. Amylin deposition in the brain: a second amyloid in Alzheimer disease? K Jackson, GA Barisone, E Diaz, LW Jin, C Decarli, F Despa, Ann Neurol 2013 [Epub ahead of print]
74. Adiponectin and coronary heart disease: a prospective study and meta-analysis. N Sattar, G Wannamethee, N Sarwar, J Tchernova, L Cherry, AM Wallace, J Danesh, PH Whincup, Circulation 2006 114 623 629 10.1161/ CIRCULATIONAHA.106.618918 16894037 (Pubitemid 44252303)
75. Adipocytokines and ischemic stroke: differential associations between stroke subtypes. BJ Kim, SH Lee, WS Ryu, CK Kim, BW Yoon, J Neurol Sci 2012 312 117 122 10.1016/j.jns.2011.08.007 21868038
76. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. S Li, HJ Shin, EL Ding, RM van Dam, JAMA 2009 302 179 188 10.1001/jama.2009.976 19584347
77. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. SG Wannamethee, PH Whincup, L Lennon, N Sattar, Arch Intern Med 2007 167 1510 1517 10.1001/archinte.167.14. 1510 17646605 (Pubitemid 47124181)
78. Visceral fat is associated with lower brain volume in healthy middle-aged adults. S Debette, A Beiser, U Hoffmann, C Decarli, CJ O'Donnell, JM Massaro, R Au, JJ Himali, PA Wolf, CS Fox, S Seshadri, Ann Neurol 2010 68 136 144 20695006
79. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: results from the Framingham Heart Study. TM van Himbergen, AS Beiser, M Ai, S Seshadri, S Otokozawa, R Au, N Thongtang, PA Wolf, EJ Schaefer, Arch Neurol 2012 69 594 600 10.1001/archneurol.2011.670 22213409
80. Leptin: a novel therapeutic target in Alzheimer's disease? D Beccano-Kelly, J Harvey, Int J Alzheimers Dis 2012 2012 594137 22254146
81. Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly. P Rajagopalan, AW Toga, CR Jack, MW Weiner, PM Thompson, Neuroreport 2013 24 58 62 10.1097/WNR.0b013e32835c5254 23238164
82. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. W Lieb, AS Beiser, RS Vasan, ZS Tan, R Au, TB Harris, R Roubenoff, S Auerbach, C DeCarli, PA Wolf, S Seshadri, JAMA 2009 302 2565 2572 10.1001/jama.2009.1836 20009056
83. Obesity, leptin, and Alzheimer's disease. EB Lee, Ann N Y Acad Sci 2011 1243 15 29 10.1111/j.1749-6632.2011.06274.x 22211890
84. Leptin and dementia over 32 years-the Prospective Population Study of Women. DR Gustafson, K Backman, L Lissner, L Carlsson, M Waern, S Ostling, X Guo, C Bengtsson, I Skoog, Alzheimers Dement 2012 8 272 277 10.1016/j.jalz.2011. 05.2411 22748937
85. The role of inflammation in vascular diseases. GW Sullivan, IJ Sarembock, J Linden, J Leukoc Biol 2000 67 591 602 10810997
86. Inflammation in neurodegenerative diseases. S Amor, F Puentes, D Baker, P van der Valk, Immunology 2010 129 154 169 10.1111/j.1365-2567.2009.03225.x 20561356
87. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. PB Gorelick, Ann N Y Acad Sci 2010 1207 155 162 10.1111/j.1749-6632.2010.05726.x 20955439
88. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. TE Strandberg, RS Tilvis, Arterioscler Thromb Vasc Biol 2000 20 1057 1060 10.1161/01.ATV.20.4.1057 10764673 (Pubitemid 30207582)
89. Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease. J Kalman, A Juhasz, G Laird, P Dickens, T Jardanhazy, A Rimanoczy, I Boncz, WL Parry-Jones, Z Janka, Acta Neurol Scand 1997 96 236 240 9325475 (Pubitemid 27402491)
90. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. R Schmidt, H Schmidt, JD Curb, K Masaki, LR White, LJ Launer, Ann Neurol 2002 52 168 174 10.1002/ana.10265 12210786 (Pubitemid 34810596)
91. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. MJ Engelhart, MI Geerlings, J Meijer, A Kiliaan, A Ruitenberg, JC van Swieten, T Stijnen, A Hofman, JC Witteman, MM Breteler, Arch Neurol 2004 61 668 672 10.1001/archneur.61.5.668 15148142 (Pubitemid 38637682)
92. Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging. G Ravaglia, P Forti, F Maioli, M Chiappelli, F Montesi, E Tumini, E Mariani, F Licastro, C Patterson, Neurobiol Aging 2007 28 1810 1820 10.1016/j.neurobiolaging.2006.08.012 17011077 (Pubitemid 47539699)
93. Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study. J Sundelof, L Kilander, J Helmersson, A Larsson, E Ronnemaa, M Degerman-Gunnarsson, H Basun, L Lannfelt, S Basu, J Alzheimers Dis 2009 18 79 87 19542629
94. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. ZS Tan, AS Beiser, RS Vasan, R Roubenoff, CA Dinarello, TB Harris, EJ Benjamin, R Au, DP Kiel, PA Wolf, S Seshadri, Neurology 2007 68 1902 1908 10.1212/01.wnl.0000263217.36439.da 17536046 (Pubitemid 46848622)
95. Prevalence of thyroid abnormalities is not increased in Alzheimer's disease. O Lopez, FJ Huff, AJ Martinez, CD Bedetti, Neurobiol Aging 1989 10 247 251 10.1016/0197-4580(89)90058-4 2787482 (Pubitemid 19180194)
96. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. S Kalmijn, KM Mehta, HA Pols, A Hofman, HA Drexhage, MM Breteler, Clin Endocrinol (Oxf) 2000 53 733 737 10.1046/j.1365-2265.2000.01146.x (Pubitemid 32096685)
97. Thyroid function and the risk of Alzheimer disease: the Framingham Study. ZS Tan, A Beiser, RS Vasan, R Au, S Auerbach, DP Kiel, PA Wolf, S Seshadri, Arch Intern Med 2008 168 1514 1520 10.1001/archinte.168.14.1514 18663163
98. The significance of thyroid-stimulating hormone and homocysteine in the development of Alzheimer's disease in mild cognitive impairment: a 6-year follow-up study. S Annerbo, LO Wahlund, J Lokk, Am J Alzheimers Dis Other Demen 2006 21 182 188 10.1177/1533317506289282 16869339 (Pubitemid 44051056)
99. Thyroid hormones, dementia, and atrophy of the medial temporal lobe. FJ de Jong, T den Heijer, TJ Visser, YB de Rijke, HA Drexhage, A Hofman, MM Breteler, J Clin Endocrinol Metab 2006 91 2569 2573 10.1210/jc.2006-0449 16636121 (Pubitemid 44024619)
100. Serum thyroid-stimulating hormone as a predictor of cognitive impairment in an elderly cohort. P Forti, V Olivelli, E Rietti, B Maltoni, G Pirazzoli, R Gatti, MG Gioia, G Ravaglia, Gerontology 2012 58 41 49 10.1159/000324522 21430364
101. Clinical review: the thyroid in mind: cognitive function and low thyrotropin in older people. EH Gan, SH Pearce, J Clin Endocrinol Metab 2012 97 3438 3449 10.1210/jc.2012-2284 22865905
102. Thyroid function and Alzheimer's disease. ZS Tan, RS Vasan, J Alzheimers Dis 2009 16 503 507 19276542
103. Alzheimer's disease: a central role for amyloid. DJ Selkoe, J Neuropathol Exp Neurol 1994 53 438 447 10.1097/00005072-199409000-00003 8083687 (Pubitemid 24276802)
104. Normal and abnormal biology of the beta-amyloid precursor protein. DJ Selkoe, Annu Rev Neurosci 1994 17 489 517 10.1146/annurev.ne.17.030194.002421 8210185 (Pubitemid 24117040)
105. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of beta-amyloidosis. JM Castellano, R Deane, AJ Gottesdiener, PB Verghese, FR Stewart, T West, AC Paoletti, TR Kasper, RB DeMattos, BV Zlokovic, DM Holtzman, Proc Natl Acad Sci U S A 2012 109 15502 15507 10.1073/pnas.1206446109 22927427
106. Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. NR Graff-Radford, JE Crook, J Lucas, BF Boeve, DS Knopman, RJ Ivnik, GE Smith, LH Younkin, RC Petersen, SG Younkin, Arch Neurol 2007 64 354 362 10.1001/archneur.64.3.354 17353377 (Pubitemid 46425689)
107. Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. O Hansson, E Stomrud, E Vanmechelen, S Ostling, DR Gustafson, H Zetterberg, K Blennow, I Skoog, J Alzheimers Dis 2012 28 231 238 21955816
108. Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. JC Lambert, S Schraen-Maschke, F Richard, N Fievet, O Rouaud, C Berr, JF Dartigues, C Tzourio, A Alperovitch, L Buee, P Amouyel, Neurology 2009 73 847 853 10.1212/WNL.0b013e3181b78448 19752451
109. Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. R Mayeux, LS Honig, MX Tang, J Manly, Y Stern, N Schupf, PD Mehta, Neurology 2003 61 1185 1190 10.1212/01.WNL.0000091890.32140.8F 14610118 (Pubitemid 37377535)
110. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. R Mayeux, MX Tang, DM Jacobs, J Manly, K Bell, C Merchant, SA Small, Y Stern, HM Wisniewski, PD Mehta, Ann Neurol 1999 46 412 416 10.1002/1531-8249(199909)46: 3<412::AID-ANA19>3.0.CO;2-A 10482274 (Pubitemid 29416281)
111. Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease. N Schupf, MX Tang, H Fukuyama, J Manly, H Andrews, P Mehta, J Ravetch, R Mayeux, Proc Natl Acad Sci U S A 2008 105 14052 14057 10.1073/pnas.0805902105 18779561
112. Midlife blood pressure, plasma beta-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. NS Shah, JS Vidal, K Masaki, H Petrovitch, GW Ross, C Tilley, RB DeMattos, RP Tracy, LR White, LJ Launer, Hypertension 2012 59 780 786 10.1161/HYPERTENSIONAHA.111.178962 22392902
113. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. J Sundelof, V Giedraitis, MC Irizarry, J Sundstrom, E Ingelsson, E Ronnemaa, J Arnlov, MD Gunnarsson, BT Hyman, H Basun, M Ingelsson, L Lannfelt, L Kilander, Arch Neurol 2008 65 256 263 10.1001/archneurol.2007.57 18268197 (Pubitemid 351240790)
114. Plasma Aβ§ssub§1-40§esub§ and Aβ§ssub§1-42§esub§ and the risk of dementia: a prospective case-cohort study. M van Oijen, A Hofman, HD Soares, PJ Koudstaal, MM Breteler, Lancet Neurol 2006 5 655 660 10.1016/S1474-4422(06)70501-4 16857570 (Pubitemid 44062411)
115. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. OL Lopez, LH Kuller, PD Mehta, JT Becker, HM Gach, RA Sweet, YF Chang, R Tracy, ST DeKosky, Neurology 2008 70 1664 1671 10.1212/01.wnl.0000306696.82017.66 18401021 (Pubitemid 351644132)
116. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. H Fukumoto, M Tennis, JJ Locascio, BT Hyman, JH Growdon, MC Irizarry, Arch Neurol 2003 60 958 964 10.1001/archneur.60.7.958 12873852 (Pubitemid 36858355)
117. Evaluation of plasma Aβ§ssub§40§esub§ and Aβ§ssub§42§esub§ as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. O Hansson, H Zetterberg, E Vanmechelen, H Vanderstichele, U Andreasson, E Londos, A Wallin, L Minthon, K Blennow, Neurobiol Aging 2010 31 357 367 10.1016/j.neurobiolaging. 2008.03.027 18486992
118. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. JJ Locascio, H Fukumoto, L Yap, T Bottiglieri, JH Growdon, BT Hyman, MC Irizarry, Arch Neurol 2008 65 776 785 10.1001/archneur.65.6.776 18541797 (Pubitemid 351831455)
119. Meta-analysis of plasma amyloid-beta levels in Alzheimer's disease. F Song, A Poljak, M Valenzuela, R Mayeux, GA Smythe, PS Sachdev, J Alzheimers Dis 2011 26 365 375 21709378
120. The future of blood-based biomarkers for Alzheimer's disease. K Henriksen, SE O'Bryant, H Hampel, JQ Trojanowski, TJ Montine, A Jeromin, K Blennow, A Lonneborg, T Wyss-Coray, H Soares, C Bazenet, M Sjogren, W Hu, S Lovestone, MA Karsdal, MW Weiner, Alzheimers Dement 2013 [Epub ahead of print]
121. Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. AJ Slooter, P de Knijff, A Hofman, M Cruts, MM Breteler, C Van Broeckhoven, LM Havekes, CM van Duijn, Neurosci Lett 1998 248 21 24 10.1016/S0304-3940(98)00339-5 9665654 (Pubitemid 28267093)
122. Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. F Song, A Poljak, J Crawford, NA Kochan, W Wen, B Cameron, O Lux, H Brodaty, K Mather, GA Smythe, PS Sachdev, PLoS One 2012 7 34078 10.1371/journal.pone.0034078 22701550
123. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. JC Lambert, S Heath, G Even, D Campion, K Sleegers, M Hiltunen, O Combarros, D Zelenika, MJ Bullido, B Tavernier, L Letenneur, K Bettens, C Berr, F Pasquier, N Fievet, P Barberger-Gateau, S Engelborghs, P De Deyn, I Mateo, A Franck, S Helisalmi, E Porcellini, O Hanon, MM de Pancorbo, C Lendon, C Dufouil, C Jaillard, T Leveillard, V Alvarez, P Bosco, et al. Nat Genet 2009 41 1094 1099 10.1038/ng.439 19734903
124. Plasma clusterin and the risk of Alzheimer disease. EM Schrijvers, PJ Koudstaal, A Hofman, MM Breteler, JAMA 2011 305 1322 1326 10.1001/jama.2011.381 21467285
125. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. M Thambisetty, A Simmons, L Velayudhan, A Hye, J Campbell, Y Zhang, LO Wahlund, E Westman, A Kinsey, A Guntert, P Proitsi, J Powell, M Causevic, R Killick, K Lunnon, S Lynham, M Broadstock, F Choudhry, DR Howlett, RJ Williams, SI Sharp, C Mitchelmore, C Tunnard, R Leung, C Foy, D O'Brien, G Breen, SJ Furney, M Ward, I Kloszewska, et al. Arch Gen Psychiatry 2010 67 739 748 10.1001/archgenpsychiatry.2010.78 20603455
126. In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. DM Holtzman, J Mol Neurosci 2004 23 247 254 10.1385/JMN:23:3:247 15181253
127. Clusterin: a forgotten player in Alzheimer's disease. T Nuutinen, T Suuronen, A Kauppinen, A Salminen, Brain Res Rev 2009 61 89 104 10.1016/j.brainresrev.2009.05.007 19651157
128. The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy. JT Yu, L Tan, Mol Neurobiol 2012 45 314 326 10.1007/s12035-012-8237-1 22274961
129. Vitamin D and Alzheimer's disease: is there a link? E Pogge, Consult Pharm 2010 25 440 450 10.4140/TCP.n.2010.440 20601349
130. Plasma proteomics for the identification of Alzheimer disease. LH Guo, P Alexopoulos, S Wagenpfeil, A Kurz, R Perneczky, Alzheimer Dis Assoc Disord 2013 [Epub ahead of print]
131. Consensus report of the Working Group on: 'Molecular and Biochemical Markers of Alzheimer's Disease'. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association, National Institute on Aging Working Group, Neurobiol Aging 1998 19 109 116 9558143
132. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. WT Hu, DM Holtzman, AM Fagan, LM Shaw, R Perrin, SE Arnold, M Grossman, C Xiong, R Craig-Schapiro, CM Clark, E Pickering, M Kuhn, Y Chen, VM Van Deerlin, L McCluskey, L Elman, J Karlawish, A Chen-Plotkin, HI Hurtig, A Siderowf, F Swenson, VM Lee, JC Morris, JQ Trojanowski, H Soares, Neurology 2012 79 897 905 10.1212/WNL.0b013e318266fa70 22855860
133. Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation. I Greco, N Day, J Riddoch-Contreras, J Reed, H Soininen, I Kloszewska, M Tsolaki, B Vellas, C Spenger, P Mecocci, LO Wahlund, A Simmons, J Barnes, S Lovestone, J Transl Med 2012 10 217 10.1186/1479-5876-10- 217 23113945